A New Vero Cell Rabies Vaccine: Results of a Comparative Trial with Human Diploid Cell Rabies Vaccine in Children

Abstract

We evaluated the immunogenicity and safety of a chromatographically purified rabies vaccine (CPRV) compared with human diploid cell rabies vaccine (HDCV) after pre-exposure immunizations (both primary and booster). Intramuscular doses of either 0.5 mL of CPRV or 1.0 mL of HDCV were given to 400 schoolchildren on days 0, 7, 28, and 365 (booster). Adequate titers of antibody (> or = 0.15 IU/mL, as defined by the Centers for Disease Control and Prevention) were observed in serum samples from all children 14 days after primary immunization with CPRV and HDCV; the antibodies persisted in all but one child up until 1 year. Fourteen days after the primary immunization series (day 42) and 7 days after booster immunization (day 372), all children had antibody titers of > or = 0.5 IU/mL. Local and systemic reactions after primary and booster immunizations occurred significantly less frequently in the CPRV group. A severe allergic reaction (angioedema) was reported in only one child after booster immunization with HDCV. CPRV has adequate immunogenicity for primary and booster pre-exposure immunizations in children and has a better safety profile than does HDCV.

Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges

“…BPL-inactivated virus vaccines against yellow fever [63], SARS-CoV [64], influenza [65] and rabies [66] were able to induce the production of neutralizing antibodies. However, BPL-inactivated influenza showed reduced hemagglutinin and neuraminidase activity [62].…”

Untitled

“…Previously published studies with larger sample sizes have consistently shown a lower frequency of local and systemic reactions with CPRV in relation to HDCV. 14,17 This trial showed comparable frequencies of local reactions and slightly higher frequencies for systemic reactions occurring within 3 days of CPRV administration. The occurrence of mild myalgia after dose 1 was higher in the CPRV group (56%) than in the HDCV group (40%).…”

“…Previously published studies 14,17 have tended to show lower GMTs with CPRV than with HDCV. However, this is thought to be clinically irrelevant, as both groups were well above the minimally acceptable seroconversion titer of Ն 0.5 IU/mL.Despite this,the GMTs reported after dose 3 in this study were similar (Table 4).…”

“…CPRV has been evaluated in several large, multicenter immunogenicity and safety studies. [14][15][16][17] These include a preexposure study in Thai children, 14 a preexposure study in European adults in comparison to PVRV, 15 a postexposure trial in the Phillipines, 16 a lot consistency study using a postexposure regimen, and a postexposure study in comparison to HDCV. 17 Here we report the immunogenicity and safety of CPRV in comparison to HDCV when administered as a typical preexposure schedule in healthy adults, i.e., the most commonly used regimen of the rabies vaccine in the US, in comparison to the most commonly used standard of care in the US.…”

COVID-19 Vaccine: The Fight Against SARS-CoV-2 Infection

“…It is known to be a well-established platform in the field of vaccine development (Delrue et al, 2012). Various vaccines, based on this platform, have been developed which include vaccines for polio, influenza and rabies with a safe record (Delrue et al, 2012;Murdin et al, 1996;Sabchareon et al, 1999;Vellozzi et al, 2009). For SARS-CoV-2, there have been 10 vaccines in clinical phase and 11 vaccines in pre-clinical phase as listed by WHO, on 9 th march 2021, (World Health Organization, 2021a).…”